AlphaCentric Advisors’s Akero Therapeutics AKRO Stock Holding History

AlphaCentric Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,000	Closed	-$405K	–	221
2023 Q3	$405K	Buy	+8,000	New	+$372K	0.23%	99

Other funds holding AKRO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AlphaCentric Advisors's AKRO Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 8,000 shares — an estimated $405K sold.

AlphaCentric Advisors first reported a position in AKRO in Q3 2023 and held it in 1 quarter. The position peaked at $405K in Q3 2023. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

AlphaCentric Advisors reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 8,000 Akero Therapeutics shares in Q4 2023, an estimated $405K.
AlphaCentric Advisors first reported a position in Akero Therapeutics in Q3 2023 and held it in 1 quarter.
AlphaCentric Advisors's Akero Therapeutics position peaked at $405K in Q3 2023.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.